Focus: Latigo Biotherapeutics is a Series B biotech company focused on non-opioid pain relief therapeutics, headquartered in Thousand Oaks, California. The company is in early-stage clinical development with a portfolio of novel analgesic candidates.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Best suited for early-stage biotech professionals seeking pain/non-opioid expertise and equity upside, but requires conviction in undisclosed clinical progress and financial runway.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Latigo Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Latigo Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles